<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19867">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723111</url>
  </required_header>
  <id_info>
    <org_study_id>knuhhermes</org_study_id>
    <nct_id>NCT01723111</nct_id>
  </id_info>
  <brief_title>Impact of Dialysis Modality on Hepcidin and Iron Metabolism</brief_title>
  <acronym>HERMES</acronym>
  <official_title>A Prospective, Multicenter, Observational Study to Evaluate the Impact of Peritoneal Dialysis Compared With Hemodialysis on Iron Metabolism and Hepcidin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Dialysis modality may influence the oxidative stress and proinflammatory cytokines in
           ESRD patients.

        -  Dialysis modality may affect hepcidin

        -  Dialysis modality may influence iron and ESA requirements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been considered that PD patients tended to be less anemic and require lower ESA dose
      than HD patients. In addition, it was also known that the level of oxidative stress and
      inflammatory cytokines tended to be lower in PD patients than HD patients. And hepcidin
      synthesis is markedly increased during inflammation. Altogether, Lower ESA requirement in PD
      patients may be associated with lower hepcidin level due to lower inflammatory state
      compared with HD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>ESA (Erythrocyte stimulating agents) dose</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare ESA dose between PD patients and HD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IV iron treatment (% of patients)</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare IV iron treatment (% of patients) between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin level</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare hepcidin level between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare hs-CRP level  between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloperoxidase</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare myeloperoxidase between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion rate</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare transfusion rate ( % of patients) between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-a</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare TNF-a  between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare IL-6 between PD patients and HD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant capacity</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare total antioxidant capacity between PD patients and HD patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <description>start PD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <description>start HD</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2 ml serum will be retained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        New ESRD patients whose dialysis treatment is expected over 3 months
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age 18 years or older

          -  Dialysis treatment was expected over 3 months

          -  In HD patients, regular hemodialysis 4 h a session more than two times a week

          -  In PD patients, over 2 exchange with more than 1.5 L solution

        Exclusion Criteria:

          -  Poorly controlled hypertension, i.e. sitting blood pressure exceeding 180/110 despite
             medication requiring hospitalization or interruption of ESA treatment

          -  Significant acute or chronic bleeding such as overt gastrointestinal bleeding within
             the previous 3 months

          -  Active malignant disease (except non-melanoma skin cancer and patients with malignant
             disease who have been disease-free for at least the 5 previous years are eligible)

          -  Acute infection

          -  Hemolysis

          -  Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)

          -  Megaloblastic anemia

          -  Platelet count &gt;500 x 109/L or &lt;100 x 109/L

          -  Pure red call aplasia

          -  Epileptic seizure during previous 3 months

          -  Women of childbearing potential without effective contraception

          -  Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol

          -  Planned elective surgery during the study period except for cataract surgery or laser
             photocoagulation

          -  Life expectancy less than 12 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Lim Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Kyungpook National University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Lim Kim</last_name>
    <phone>+82-53-420-5553</phone>
    <email>ylkim@knu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Ho Kim</last_name>
      <phone>+82-53-940-7221</phone>
      <email>shkim@fatima.or.kr</email>
    </contact>
    <investigator>
      <last_name>Sung-Ho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Yeup Han</last_name>
      <email>dr4kidney@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Yeup Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-Young Do</last_name>
      <email>jydo@med.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jun-Young Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Lim Kim</last_name>
      <phone>+82-53-420-5553</phone>
      <email>ylkim@knu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong-Lim Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail. 2009;31(10):876-83. doi: 10.3109/08860220903216071.</citation>
    <PMID>20030521</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 1, 2013</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Yong-Lim Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>hepcidin</keyword>
  <keyword>ESA</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>iron metabolism</keyword>
  <keyword>dialysis modality</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepcidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
